Asymmetry Capital Management L.P. bought a new position in Twist Bioscience Corp (NASDAQ:TWST) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 23,733 shares of the company’s stock, valued at approximately $550,000. Twist Bioscience accounts for about 0.9% of Asymmetry Capital Management L.P.’s portfolio, making the stock its 24th biggest position.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its holdings in Twist Bioscience by 9.7% during the first quarter. JPMorgan Chase & Co. now owns 1,050,458 shares of the company’s stock worth $24,350,000 after purchasing an additional 93,144 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in Twist Bioscience by 51.6% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 204,720 shares of the company’s stock worth $4,745,000 after purchasing an additional 69,696 shares during the last quarter. Emerald Advisers LLC boosted its holdings in Twist Bioscience by 42.7% during the first quarter. Emerald Advisers LLC now owns 235,138 shares of the company’s stock worth $5,450,000 after purchasing an additional 70,391 shares during the last quarter. Deutsche Bank AG acquired a new position in Twist Bioscience during the fourth quarter worth $151,000. Finally, Geode Capital Management LLC acquired a new position in Twist Bioscience during the fourth quarter worth $1,717,000. Hedge funds and other institutional investors own 23.39% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of Twist Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, March 20th.
Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Tuesday, April 30th. The company reported ($0.93) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.03) by $0.10. The business had revenue of $13.56 million for the quarter, compared to analyst estimates of $11.88 million. As a group, equities research analysts predict that Twist Bioscience Corp will post -3.65 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Asymmetry Capital Management L.P. Buys New Holdings in Twist Bioscience Corp (TWST)” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/4347000/asymmetry-capital-management-l-p-buys-new-holdings-in-twist-bioscience-corp-twst.html.
Twist Bioscience Company Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corp (NASDAQ:TWST).
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.